Please login to the form below

Not currently logged in
Email:
Password:

BioMarin rated 'Outperform' on Kuvan phase III data

Robert W Baird analysts reiterate their "Outperform" rating on US-based BioMarin Pharmaceutical and set the target price USD 27

Robert W Baird analysts have reiterated their "Outperform" rating on US-based BioMarin Pharmaceutical and set the target price USD 27.

In a research note published on 14 August, the analysts mention that the full publication of Kuvan's (sapropterin) phase III study may result in the uptake and increased usage in older phenylketonuria (PKU) patients.

PKU is an inherited metabolic disease caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). Insufficient quantities or reduced activity of PAH results in elevated levels of phenylalanine (Phe) in the blood. Sustained elevated blood Phe levels can result in serious neurological damage.

The US Kuvan revenue estimate for 2008 is set at USD 67m. According to the published data, the drug could be used for lifelong treatment, which may lend upside for the use of Kuvan as patients age, added analysts.

The final results from the Kuvan pivotal phase III clinical trial were published in the 11 August issue of The Lancet. The study suggests that treatment with the drug results in significant reductions in blood Phe levels in some PKU patients. Kuvan is being developed in partnership with Merck Serono, a division of German pharmaceutical company, Merck KGaA.

Jean-Jacques Bienaime, CEO of BioMarin, said in a Q2 FY07 conference call: "Our Kuvan programme is progressing on track, with three important milestones achieved recently: submission of the NDA filing, initiation of the expanded access programme, and receipt of priority review status.

The expanded access programme is actively enrolling patients, and we are hopeful that Kuvan will receive FDA approval by the end of November 2007."

15th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics